Skip to main content

Table 2 MHT use at study entry and breast cancer incidence by intrinsic-like subtypes

From: Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study

 

Breast cancer overall (n = 7,844)

Luminal A-like

(n = 3,784)

Luminal B-like

(n = 1,480)

HER2 + 

(n = 264)

TNBC

(n = 500)

phet2

 

n cases

HR (95% CI)1

n cases

HR (95% CI)1

n cases

HR (95% CI)1

n cases

HR (95% CI)1

n cases

HR (95% CI)1

 

MHT use overall

           

Never use

4,297

Ref

2,113

Ref

845

Ref

155

Ref

297

Ref

 

  Ever use

3,547

1.24 (1.18–1.29)

1,671

1.16 (1.10–1.25)

635

1.13 (1.02–1.26)

109

1.07 (0.83–1.37)

203

1.03 (0.86–1.23)

0.51

    Current

2,782

1.35 (1.29–1.42)

1,310

1.32 (1.23–1.41)

464

1.17 (1.04–1.31)

77

1.05 (0.80–1.39)

139

0.99 (0.80–1.21)

0.02

    Former

765

0.95 (0.88–1.02)

361

0.83 (0.75–0.93)

171

1.04 (0.88–1.23)

32

1.12 (0.76–1.64)

64

1.12 (0.85–1.48)

0.08

  Duration

           

     < 5 yrs

2,250

1.16 (0.10–1.22)

984

1.06 (0.98–1.14)

416

1.13 (1.00–1.27)

78

1.14 (0.86–1.50)

128

0.97 (0.79–1.20)

 

     ≥ 5 yrs

1,243

1.40 (1.31–1.49)

656

1.37 (1.26–1.50)

212

1.15 (0.99–1.34)

30

0.94 (0.63–1.40)

71

1.13 (0.87–1.46)

 

    Per 1 yr

7,790

1.03 (1.03–1.04)

3,753

1.03 (1.02–1.04)

1,473

1.02 (1.00–1.03)

263

1.00 (0.96–1.04)

496

1.01 (0.98–1.03)

0.04

EPT use

           

Never use

4,297

Ref

2,113

Ref

845

Ref

155

Ref

297

Ref

 

  Ever use

2,599

1.32 (1.25–1.38)

1,248

1.26 (1.17–1.35)

464

1.19 (1.06–1.34)

82

1.16 (0.88–1.52)

147

1.08 (0.88–1.32)

0.45

    Current

2,120

1.44 (1.36–1.52)

1,012

1.41 (1.31–1.52)

352

1.23 (1.09–1.40)

58

1.09 (0.81–1.49)

107

1.06 (0.85–1.32)

0.04

    Former

479

0.96 (0.87–1.05)

236

0.86 (0.75–0.99)

112

1.09 (0.89–1.33)

24

1.34 (0.86–2.06)

40

1.13 (0.81–1.57)

0.11

  Duration

           

     < 5 yrs

1,559

1.22 (1.15–1.29)

688

1.11 (1.02–1.22)

288

1.18 (1.03–1.35)

56

1.22 (0.89–1.66)

91

1.04 (0.82–1.32)

 

     ≥ 5 yrs

1,028

1.49 (1.39–1.60)

553

1.48 (1.35–1.63)

175

1.22 (1.03–1.44)

25

1.01 (0.66–1.54)

55

1.12 (0.84–1.50)

 

    Per 1 yr

6,884

1.04 (1.03–1.05)

3,354

1.04 (1.03–1.05)

1,308

1.02 (1.01–1.04)

236

1.01 (0.97–1.06)

443

1.01 (0.98–1.04)

0.05

ET use only

           

Never use

4,297

Ref

2,113

Ref

845

Ref

155

Ref

297

Ref

 

  Ever use

262

0.96 (0.85–1.09)

122

0.89 (0.74–1.06)

52

0.97 (0.73–1.29)

12

1.25 (0.69–2.26)

15

0.80 (0.48–1.35)

0.68

    Current

224

1.04 (0.91–1.19)

102

0.95 (0.78–1.16)

47

1.12 (0.83–1.50)

9

1.18 (0.60–2.32)

12

0.81 (0.45–1.45)

0.68

    Former

38

0.68 (0.49–0.94)

20

0.65 (0.42–1.01)

5

0.43 (0.18–1.04)

3

1.51 (0.48–4.74)

3

0.76 (0.24–2.37)

0.39

  Duration

           

     < 5 yrs

164

0.97 (0.83–1.13)

78

0.95 (0.76–1.20)

29

0.90 (0.62–1.30)

8

1.34 (0.66–2.72)

8

0.70 (0.35–1.41)

 

     ≥ 5 yrs

96

0.95 (0.78–1.17)

43

0.78 (0.58–1.06)

22

1.05 (0.69–1.61)

4

1.13 (0.42–3.05)

7

0.98 (0.46–2.08)

 

    Per 1 yr

4,557

0.99 (0.97–1.01)

2,234

0.98 (0.95–1.01)

896

1.00 (0.96–1.04)

167

0.99 (0.89–1.10)

312

0.98 (0.90–1.06)

0.85

Cumulative dose

           

Never use

4,297

Ref

2,113

Ref

845

Ref

155

Ref

297

Ref

 

Estrogen (E2-equivalence)

           

     < 5 g

1,999

1.21 (1.15–1.28)

948

1.23 (1.14–1.33)

347

1.13 (1.00–1.29)

69

1.29 (0.97–1.74)

112

1.01 (0.81–1.27)

0.49

    5–10 g

827

1.36 (1.26–1.47)

399

1.45 (1.29–1.62)

154

1.39 (1.16–1.66)

22

1.24 (0.78–1.97)

48

1.21 (0.88–1.66)

0.66

     > 10 g

192

1.51 (1.30–1.75)

103

1.79 (1.46–2.18)

34

1.46 (1.03–2.07)

5

1.39 (0.57–3.43)

6

0.74 (0.33–1.66)

0.19

Progestin (NETA-equivalence)

           

     < 1 g

1,411

1.20 (1.13–1.28)

634

1.16 (1.06–1.27)

257

1.18 (1.02–1.36)

46

1.19 (0.85–1.66)

92

1.18 (0.93–1.50)

0.97

    1–2 g

695

1.36 (1.25–1.47)

361

1.55 (1.38–1.74)

112

1.19 (0.97–1.45)

18

1.18 (0.72–1.95)

33

0.99 (0.68–1.43)

0.04

     > 2 g

608

1.66 (1.52–1.82)

304

1.87 (1.65–2.12)

107

1.60 (1.30–1.97)

18

1.79 (1.08–2.98)

24

1.02 (0.66–1.56)

0.09

E2 dose < 5 g

           

    NETA dose < 1 g

1,306

1.20 (1.14–1.28)

589

1.16 (1.06–1.27)

237

1.17 (1.01–1.35)

43

1.20 (0.85–1.69)

79

1.09 (0.85–1.41)

0.98

    NETA dose ≥ 1 g

439

1.47 (1.33–1.63)

233

1.73 (1.51–1.98)

66

1.20 (0.93–1.55)

12

1.36 (0.75–2.48)

18

0.93 (0.57–1.50)

0.03

E2 dose ≥ 5 g

           

    NETA dose < 1 g

93

1.20 (0.98–1.48)

40

1.14 (0.84–1.57)

18

1.29 (0.80–2.05)

3

1.30 (0.41–4.09)

11

2.23 (1.22–4.09)

0.27

    NETA dose ≥ 1 g

862

1.49 (1.38–1.61)

431

1.66 (1.48–1.84)

153

1.44 (1.20–1.72)

23

1.39 (0.88–2.19)

39

1.04 (0.74–1.48)

0.09

  1. 1Adjusted for age (underlying time scale), BMI, parity, age at first birth, age at menarche, family history, smoking, physical activity, education
  2. 2p heterogeneity between intrinsic-like subtypes; Wald test by competing risks analysis
  3. CI confidence interval, ET, estrogen therapy, EPT estrogen-progestin therapy, E2 estradiol, HER2 human epidermal growth factor receptor 2, HR hazard ratio MHT menopausal hormone therapy NETA norethisterone acetate, TNBC triple-negative breast cancer
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us